TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02865824
Drug: Discontinue thienopyridine
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
Study: NCT01717040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
Study: NCT02691676
Drug: Plasmalyte
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
Study: NCT04264533
Drug: VC
Normalized name: VCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
Study: NCT01116011
Drug: AZD7268
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, BID
Study: NCT01116011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, BID
Study: NCT03234686
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
Study: NCT02235480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04388358
Drug: Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were treated with mixed formula of Chinese medicine for one month
Study: NCT01939990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo looks like the study drug but it does not contain active ingredients.
Study: NCT03522649
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
Study: NCT03522649
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
Study: NCT04657315
Drug: MSC11FCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration
Study: NCT02560051
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
Study: NCT00430170
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine 4mg/kg iv
Study: NCT01216865
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
Study: NCT02867358
Drug: KT07 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03196557
Drug: Prenisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03196557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on dose on specified days
Study: NCT02583048
Drug: Multidrug Background Treatment (MBT) for TB
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
Study: NCT00148746
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02155257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00414726
Drug: NBO (Normobaric Oxygen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Study: NCT02328040
Drug: Placebo and Insulin monotherapy via CL
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
Study: NCT02107196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
Study: NCT00564031
Drug: Femanest
Normalized name: Femtest
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/day
Study: NCT00564031
Drug: gestapuran
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/day
Study: NCT00564031
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT00564031
Drug: Femanest plus Gestapuran
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined daily
Study: NCT03119662
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL saline, followed by a 10 mL saline flush.
Study: NCT03362008
Drug: Champix®
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Champix®
Study: NCT03016806
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg or 60 mg/kg
Study: NCT00813735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily at bedtime
Study: NCT01389713
Drug: GnRH analog and recombinant human FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
Study: NCT01569113
Drug: placebo + ethinylestradiol/levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
Study: NCT03420092
Drug: Selected form (Form 2 - 5) of AZD5718 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
Study: NCT01085981
Drug: arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
Study: NCT01085981
Drug: Topical study cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
Study: NCT01134549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single intravenous (IV) injection
Study: NCT01290965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet given once or three times daily for 15 consecutive days
Study: NCT03441100
Drug: IMA202 Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
Study: NCT03067168
Drug: normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
Study: NCT02994836
Drug: Anti-TNF discontinuation: Physiological saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
Study: NCT02994836
Drug: Anti-TNF discontinuation: Physiological saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
Study: NCT03013036
Drug: fentanyl and rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02268604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01080820
Drug: CMX157
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
Study: NCT01080820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
Study: NCT01924286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03944954
Drug: Marinol 10Mg Capsule TMS Sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals will receive 10mg dose and sham TMS.
Study: NCT00613457
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
Study: NCT00613457
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/sqm i.v. x 4 doses in Protocol II and III
Study: NCT00613457
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Study: NCT00613457
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Study: NCT00763321
Drug: ABT-712
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-712 extended-release tablet
Study: NCT00763321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT01302873
Drug: BGG492A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02486757
Drug: transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01554930
Drug: Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
Study: NCT01017952
Drug: FF/GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Study: NCT01017952
Drug: GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long Acting Beta Agonist(LABA) Inhalation Powder
Study: NCT01965496
Drug: PEX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: A injection administered subcutaneously
Study: NCT02265679
Drug: BIIL 284 BS, low dose, pediatric patients
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03315533
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
Study: NCT02022306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02793232
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo suspension administered as single dose
Study: NCT00235898
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02793232
Drug: Placebo multiple ascending dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo suspension administered daily for 14 consecutive days.
Study: NCT03310021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01962805
Drug: Proellex Formulation A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01962805
Drug: Proellex Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01767155
Drug: AEZS-108 / zoptarelin doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
Study: NCT01767155
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
Study: NCT03928600
Drug: Dinoprostone 10mg insert OR
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application for 24h of Dinoprostone 10mg insert
Study: NCT01337427
Drug: BIIB017
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
Study: NCT00177580
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02518750
Drug: Intrathecal Triples
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT as ITMHA.
Study: NCT02518750
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intrathecally (IT) or IV.
Study: NCT02518750
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT00264914
Drug: SR121463B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01800838
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo PDT
Study: NCT01905605
Drug: phosphatidylcholine supplementation
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphatidylcholine concentrate 700 mg twice per day
Study: NCT01905605
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
Study: NCT00067327
Drug: Inosine
Normalized name: Inosine
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01753362
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00974350
Drug: SABER-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
Study: NCT01807026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02788357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
Study: NCT01627639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00694044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 21 days
Study: NCT03248128
Drug: FF/VI via ELLIPTA DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
Study: NCT03248128
Drug: FF via ELLIPTA DPI
Normalized name: Eclipta prostrata leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
Study: NCT01608906
Drug: low dose intravenous heparin (LDIVH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
Study: NCT01608906
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
Study: NCT04234178
Drug: Epidural
Normalized name: Epidural 17g 3.5"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
Study: NCT03892447
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine3～5 ug/kg·min,iv,3 h/d,14d
Study: NCT03254966
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT03254966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00804973
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, once
Study: NCT00301327
Drug: Summers 5% L.A.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02002130
Drug: Placebo GABA and Placebo GAD-alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
Study: NCT00169130
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00169130
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01087567
Drug: Routine Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
Study: NCT02061358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, single dose
Study: NCT00473616
Drug: AZD7762
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01812239
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
Study: NCT01458886
Drug: Placebo matching Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs a.m. via Respimat inhaler
Study: NCT00492583
Drug: Bifidobacterium lactis (BB-12)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
Study: NCT00492583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
Study: NCT01939743
Drug: Diclofenac suppository plus lidocaine gel
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04403282
Drug: Eflornithine Topical
Normalized name: eflornithine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
Study: NCT04403282
Drug: Placebo Eflornithine Topical
Normalized name: eflornithine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
Study: NCT00824512
Drug: EGb 761 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761® 120 mg bid, orally for 12 to 14 weeks
Study: NCT00824512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet BID, orally for 12 to 14 weeks
Study: NCT01336088
Drug: ADX48621
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01336088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00095160
Drug: 852A
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03781596
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
Study: NCT01647620
Drug: DPOC-4088
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
Study: NCT01647620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10-day oral dosing of matching placebo prolonged release tablet.
Study: NCT00795314
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)